COSMIC, chemotherapy plus ofatumumab at standard or mega-dose in chronic lymphocytic leukaemia, a phase II randomised study

被引：0

作者：

Allsup, David ^{[1
,2
]}

Howard, Dena ^{[3
]}

Emmerson, Jake ^{[3
]}

Hockaday, Anna ^{[3
]}

Rawstron, Andy ^{[4
]}

Oughton, Jamie B. ^{[3
]}

Bloor, Adrian ^{[5
]}

Phillips, David ^{[3
]}

Nathwani, Amit ^{[6
]}

Paneesha, Shankara ^{[7
]}

Turner, Deborah ^{[8
]}

Munir, Talha ^{[9
]}

Hillmen, Peter ^{[9
]}

机构：

[1] Hull Univ Teaching Hosp, Haematol, Kingston Upon Hull, Yorks, England

[2] Hull York Med Sch, Ctr Atherothrombosis & Metab Dis, Kingston Upon Hull, N Humberside, England

[3] Univ Leeds, Clin Trials Res Unit, Leeds, W Yorkshire, England

[4] St James Univ Hosp, Leeds, W Yorkshire, England

[5] Christie NHS Fdn Trust, Manchester, Lancs, England

[6] Univ Coll London Hosp, London, England

[7] Birmingham Heartlands Hosp, Birmingham, W Midlands, England

[8] Torbay Dist Hosp, Torquay, England

[9] St James Univ Hosp, St James Inst Oncol, Leeds, W Yorkshire, England

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2021年 / 194卷 / 03期

关键词：

chronic lymphocytic leukaemia; chemotherapy; clinical trial; monoclonal antibody; minimal residual disease; FLUDARABINE; CYCLOPHOSPHAMIDE; CHLORAMBUCIL; RITUXIMAB;

D O I：

10.1111/bjh.17526

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：646 / 650

页数：5

共 50 条

[1] COSMIC, a phase II randomised study investigating the efficacy of standard or high-dose ofatumumab in combination with chemotherapy in patients with relapsed chronic lymphocytic leukaemia
Allsup, David
Howard, Dena
Munir, Talha
Hockaday, Anna
Rawstron, Andy
Collett, Laura
McParland, Lucy
Oughton, Jamie
Bloor, Adrian
Phillips, David
Nathwani, Amit
Shankara, Paneesha
Turner, Deborah
Hillmen, Peter
[J]. LEUKEMIA & LYMPHOMA, 2017, 58 : 112 - 113
[2] Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trial
Howard, Dena R.
Munir, Talha
Hockaday, Anna
Rawstron, Andy C.
Collett, Laura
Oughton, Jamie B.
Allsup, David
Bloor, Adrian
Phillips, David
Hillmen, Peter
[J]. TRIALS, 2016, 17
[3] Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trial
Dena R. Howard
Talha Munir
Anna Hockaday
Andy C. Rawstron
Laura Collett
Jamie B. Oughton
David Allsup
Adrian Bloor
David Phillips
Peter Hillmen
[J]. Trials, 17
[4] A PHASE II RANDOMISED STUDY INVESTIGATING THE EFFICACY OF STANDARD OR HIGH-DOSE OFATUMUMAB IN COMBINATION WITH CHEMOTHERAPY IN RELAPSED CHRONIC LYMPHOCYTIC LEUKAEMIA
Allsup, D.
Howard, D.
Munir, T.
Hockaday, A.
Rawstron, A.
Collett, L.
McParland, L.
Oughton, J.
Bloor, A.
Phillips, D.
Nathwani, A.
Shankara, P.
Turner, D.
Hillmen, P.
[J]. HAEMATOLOGICA, 2017, 102 : 72 - 72
[5] Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study
van Oers, Marinus H. J.
Kuliczkowski, Kazimierz
Smolej, Lukas
Petrini, Mario
Offner, Fritz
Grosicki, Sebastian
Levin, Mark-David
Gupta, Ira
Phillips, Jennifer
Williams, Vanessa
Manson, Stephanie
Lisby, Steen
Geisler, Christian
[J]. LANCET ONCOLOGY, 2015, 16 (13): : 1370 - 1379
[6] Dose intensification and molecular responses in patients with chronic lymphocytic leukaemia: a phase II single centre study
Schey, SA
Ahsan, G
Jones, R
[J]. BONE MARROW TRANSPLANTATION, 1999, 24 (09) : 989 - 993
[7] Dose intensification and molecular responses in patients with chronic lymphocytic leukaemia: a phase II single centre study
SA Schey
G Ahsan
R Jones
[J]. Bone Marrow Transplantation, 1999, 24 : 989 - 993
[8] Screened selection design for randomised phase II oncology trials: an example in chronic lymphocytic leukaemia
Yap, Christina
Pettitt, Andrew
Billingham, Lucinda
[J]. BMC MEDICAL RESEARCH METHODOLOGY, 2013, 13
[9] Screened selection design for randomised phase II oncology trials: an example in chronic lymphocytic leukaemia
Christina Yap
Lucinda Billingham
Andrew Pettitt
[J]. Trials, 12 (Suppl 1)
[10] Screened selection design for randomised phase II oncology trials: an example in chronic lymphocytic leukaemia
Christina Yap
Andrew Pettitt
Lucinda Billingham
[J]. BMC Medical Research Methodology, 13

← 1 2 3 4 5 →